Novel Indazole Compounds for Glucose-Dependent Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes treatments, particularly insulin therapy, face challenges such as limited administration routes, constant glycemic level control, local allergic reactions, and side effects like hypoglycemia, hepatotoxicity, and gastrointestinal issues, necessitating the development of novel compounds that induce glucose-dependent insulin release without basal glucose secretion.
Innovation Solution
Development of novel indazole compounds, specifically 5-Chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indazole and its derivatives, which are synthesized through a process involving isatin conversion to indazole carboxylic acid, subsequent amide formation, cyano compound generation, and reaction with diamines, offering insulinotropic activity and glucose-dependent insulin secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin therapy is used to treat diabetes, then blood glucose levels can be controlled, but it causes local allergic reactions, hypoglycemia, and requires constant glycemic level control
Solution Approach 1:
The patent changes the chemical parameters by developing novel indazole compounds with specific molecular structures (Formula I) that modify the insulin secretion mechanism. These compounds induce glucose-dependent insulin release, changing the pharmacological parameter from constant insulin action to glucose-responsive insulin secretion, thereby reducing hypoglycemia risk while maintaining glucose control efficacy
Solution Approach 2:
The indazole compounds act as intermediary substances that mediate between glucose levels and insulin secretion. They do not directly provide insulin but rather stimulate the pancreas to release insulin in response to glucose, creating an indirect pathway that mimics physiological insulin secretion and reduces adverse effects associated with direct insulin administration
2Reliability
If conventional diabetes treatments are used, then glycemic control can be achieved, but they cause side effects like hepatotoxicity and gastrointestinal issues
Solution Approach 1:
The patent introduces new chemical compounds with distinct molecular structures (indazole core with specific substituents) that change the pharmacokinetic and pharmacodynamic parameters. These structural changes result in a favorable safety profile by avoiding metabolic pathways that cause hepatotoxicity and gastrointestinal irritation associated with conventional antidiabetic drugs
3Reliability
If insulin therapy is administered, then diabetes symptoms can be managed, but it requires parenteral administration and constant monitoring
Solution Approach 1:
The indazole compounds serve as oral mediators that facilitate endogenous insulin secretion. By taking oral tablets rather than parenteral insulin, patients eliminate the need for injections and continuous monitoring. The compounds work as intermediaries to trigger natural insulin release in response to meals, simplifying the treatment regimen while maintaining effective glycemic control
Data Source
Figure 1a~1c
Figure 2a~2b
Figure 3a~3b
AI summary
The patent discloses novel indazole compounds of general formula1 and analogues thereof, use thereof for the treatment of diabetes, diabetic complications, cardiovascular dysfuntion or related diseases, pharmaceutical compositions comprising them and processes for their preparation.